{"entity":{"id":"nct05950165","kind":"trial","name":"A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Ly","aka":[],"tldr":"A phase 1/2 trial of Lenalidomide in hodgkin lymphoma and non-hodgkin lymphoma, run by Cho Pharma Inc., active and no longer recruiting.","summary":"A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma is a phase 1/2 interventional study registered as NCT05950165 by Cho Pharma Inc., with 37 participants planned, started 2020-01-15 and due to reach its primary completion in 2026-12-23. Interventions recorded: CHO-H01, CHO-H01 at RP2D, Lenalidomide. Conditions listed: Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05950165","url":"https://clinicaltrials.gov/study/NCT05950165"}],"tags":["ctgov-ingest"],"related":[],"cancers":["hodgkin-lymphoma","non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["lenalidomide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05950165","phase":"1/2","setting":"A Phase I/IIa, Open-label, Multicenter Study of the Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide to Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma","sponsor":"Cho Pharma Inc.","enrolled":37,"outcomes":[]},"route":"/trials/nct05950165/","neighbours":{"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"}]}}